AnaptysBio (ANAB) hosted a webcast to discuss positive rosnilimab Phase 2b rheumatoid arthritis results and featured two leading rheumatologists, noting strong 28-week efficacy in both biologic-naive and-experienced patients vs. Phase 3 active comparator trials, Leerink tells investors in a research note. The firm notes that a durable benefit was observed off the drug for at least two months post-treatment, and a separate EULAR abstract revealed disappointing ulcerative colitis results for competitor Johnson & Johnson’s (JNJ) PD-1 agonist JNJ-67484703, which appears less potent and its data in RA appears weaker cross-trial relative to rosnilimab. Leerink has an Outperform rating on AnaptysBio shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio’s Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade
- AnaptysBio upgraded to Buy from Neutral at H.C. Wainwright
- Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
- Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise
- AnaptysBio Reports Positive Phase 2b Trial Results